SDV2102 is an innovative antibody-drug conjugate (ADC) that binds to prostate-specific membrane antigen (PSMA), a protein overexpressed in mCRPC tumors, delivering a powerful cancer-killing agent directly to the disease.
Early tests in animals suggest SDV2102 could be a game-changer, offering hope to patients with limited options in the fight against this aggressive cancer.

SDV2102 stands out due to its unique design. It uses a novel antibody, D10, chosen for its exceptional ability to bind to PSMA, paired with monomethyl auristatin E (MMAE), a drug that disrupts cancer cell division and is particularly effective against mCRPC.
Unlike traditional ADCs, which typically carry four drug molecules per antibody, SDV2102 has a drug-to-antibody ratio of just one. This allows doctors to use higher doses without increasing toxic side effects, making the treatment both more potent and safer.

What makes SDV2102 especially promising is its versatility. In patient-derived tumor models with low to moderate PSMA levels—some with as few as 25,000 PSMA receptors per cell—the drug still showed strong anti-tumor effects. This suggests SDV2102 could help a wide range of mCRPC patients, even those whose tumors don’t have uniformly high PSMA expression, a limitation for some competing therapies.
Safety is another strong suit. In rat studies, SDV2102 behaved much like the D10 antibody alone, circulating in the body without breaking down prematurely, which ensures it reaches tumors effectively. In non-human primates, doses up to 24 mg/kg caused no major side effects, and the maximum safe dose wasn’t even reached, indicating a wide safety margin.

Source.